

## Quintain Consulting News and Events 2009

### **December 2009: Quintain Consulting in Discussions with US Company for InCellution IP**

Quintain Consulting has entered into discussions with a US-based company, for out-licensing of the InCellution IP, which was assigned into Quintain from Melbourne-based company [AdAlta](#) in September 2009. The technology enables the improvement in performance - specificity, sensitivity and stability - of therapeutic and diagnostic reagents, such as antibodies and other proteins. The discussions are currently focused around applications for therapeutic reagents. Quintain is also in discussions with an Australian company, for licensing of this technology for diagnostic applications.

### **November 2009: Quintain Consulting and BioDetectors Enter Collaboration Agreement**

Quintain Consulting has entered into an Agreement with BioDetectors Pty Ltd, to assist the Sydney-based diagnostics company with the commercialisation of its technology portfolio. BioDetectors has access to a number of diagnostic platforms, which have the capability to offer vastly improved detection of substances such as alcohol, drugs of abuse and infectious diseases. Please visit the [BioDetectors](#) website for further information.

### **October 2009: AusBiotech 2009**

The premier annual biotechnology event for the Asia Pacific region, [AusBiotech 2009](#), is approaching, with the conference running from 27-30 October at the Melbourne Convention and Exhibition Centre. The event features a three day conference program, Bioindustry Exhibition and Business Matching Program in addition to a variety of Satellite events. If you would like to meet with Quintain Consulting during your time in Melbourne please don't hesitate to [contact us](#).

### **September 2009: Quintain Consulting Visit to New Zealand**

Dr's Bob Irving and Jeanette Pritchard are planning visits to key collaborators and institutes who are involved in BioNanotechnology developments, during an upcoming trip to New Zealand on 14-16th September. Bob and Jeanette will spend time in Wellington, during which they will meet with [Trinity BioActives](#) amongst others. This will coincide with the completion of the first phase of the collaboration between Trinity and NanoVentures Australia, which is focused on the development of a rapid point-of-care diagnostic test for meningococcal disease.

### **September 2009: Quintain Consulting attending Nanotechnology Stakeholder Day**

Dr Jeanette Pritchard has been invited to attend the upcoming the Australian Academy of Sciences Nanotechnology Stakeholder Day. The event is being held in Canberra on 25th September and will be attended by representatives from both industry and academia.

### **September 2009: Quintain Consulting secures Assignment of IP from AdAlta**

Quintain Consulting is delighted to announce that it has secured assignment of the InCellution Australian-granted IP from local biotechnology company [AdAlta](#). The technology enables the creation of improved diagnostic and therapeutic antibodies and reagents.